Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-05-31 Board/Management Inform…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding a change in senior management personnel, specifically the resignation of a Senior Vice President (R&D). It references compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including management changes. The document includes details about the resignation, effective dates, and annexures with further information. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of announcements about changes in the company's board or senior management.
2024-05-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for the fourth quarter and fiscal year 2024 of Gland Pharma Limited. It includes management commentary, financial performance data, business highlights, strategic updates, and Q&A format typical of earnings call transcripts. The document explicitly states it is the transcript of the earnings call held on May 22, 2024, and includes detailed discussion of quarterly and annual financial results, operational updates, and forward-looking statements. This matches the definition of a Call Transcript (CT). The document length is substantial (15,000 characters), and it contains the full text of the call, not just an announcement or summary, so it is not an Earnings Release (ER) or Report Publication Announcement (RPA). Therefore, the correct classification is CT with high confidence.
2024-05-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter dated May 27, 2024, addressed to stock exchanges, informing them about the schedule of an upcoming Analyst/Institutional Investor Meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content is purely an announcement of a meeting schedule with no financial data, no report attached or referenced as being published, and no detailed presentation included. The document length is only 1540 characters, indicating it is a brief notice rather than a full report or transcript. Therefore, this document fits best under the category of Investor Presentation (IP) as it relates to investor meetings and presentations, but since it only announces the schedule and does not contain the presentation itself, it is not a full Investor Presentation. However, none of the other categories fit better. The closest and most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement about investor meetings, since it is a compliance disclosure without substantive financial or presentation content.
2024-05-27 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the completion of a US FDA inspection at a company facility with zero 483 observations. It is dated May 24, 2024, and signed by the Company Secretary and Compliance Officer. There is no financial data, no detailed report, no voting results, no management changes, no earnings information, or any other detailed corporate filing content. The document serves as a regulatory announcement to inform the market and regulators about the inspection outcome. Given the short length (1196 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-05-24 English
Copy of Newspaper Publication
Regulatory Filings
2024-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the earnings call recording for the quarter and financial year ended March 31, 2024. It references the date of the call and provides a weblink to the audio recording. The document does not contain the transcript or detailed financial data but is an announcement about the availability of the earnings call recording. The length is short (1456 characters), and it serves as a notification rather than the full transcript. According to the classification rules, announcements about earnings calls or their recordings are best classified as Call Transcript (CT) if the full transcript is provided, but since this is only a notification of the recording availability, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory announcement without substantive financial data or transcript content.
2024-05-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.